Chronic bilateral electrical stimulation of the subthalamic nucleus for the treatment of advanced Parkinson's disease.
Preliminary reports in patients with Parkinson's disease (PD) showed that subthalamic nucleus (STN) stimulation was able to reverse parkinsonian state. Since 1998 we evaluated the safety and the efficacy of STN stimulation in 7 patients affected by advanced PD. All patients were included using CAPIT protocol. Motor functions and quality of life were evaluated, before and after surgery, with UPDRS and PDQ38, respectively. At the 6-month follow-up, the off medication/on stimulation UPDRS motor score improved by 50.6% and the on medication/on stimulation by 20.3%. Motor fluctuations were reduced by 57.2% and dyskinesias by 73.5%. The total L-dopa equivalent daily dose was reduced by 40.7%. PDQ38 ameliorated by 49.9%. We did not observe any perioperatory complication and only mild and tolerable side effects after stimulation.
Capus
L
L
Department of Neurology, Cattinara Hospital, University of Trieste, Italy.
Melatini
A
A
Zorzon
M
M
Torre
P
P
Carraro
N
N
Moretti
D
D
Gioulis
M
M
Moretti
R
R
Sarra
M V
MV
Marsala
S Z
SZ
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003072:Cognition Disorders / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D004599:Electric Stimulation Therapy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D004567:Electrodes, Implanted / Q000009:adverse effects / Q000592:standards*; D005260:Female; D007839:Functional Laterality / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D019635:Neurosurgical Procedures / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D010300:Parkinson Disease / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D011788:Quality of Life; D020127:Recovery of Function / Q000502:physiology; D020531:Subthalamic Nucleus / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D016896:Treatment Outcome
D000978:Antiparkinson Agents